Enterprise Value

6.743B

Cash

434.9M

Avg Qtr Burn

-131.9M

Short % of Float

11.86%

Insider Ownership

5.37%

Institutional Own.

92.14%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NULIBRY (Fosdenopterin) (BBP-870/ORGN001) Details
Molybdenum cofactor deficiency type A

Approved

Quarterly sales

Acoramidis (AG10) Details
Transthyretin Amyloid Cardiomyopathy

PDUFA

Approval decision

Infigratinib Details
Achondroplasia

Phase 3

Data readout

Encaleret Details
Autosomal Dominant Hypocalcemia Type 1

Big Mover™

Susp. Mover™

Phase 3

Data readout

BBP-418 Details
Limb-Girdle Muscular Dystrophy

Phase 3

Data readout

BBP-398 + OPDIVO Details
Solid tumor/s, Lung cancer, Non-small cell lung carcinoma

Phase 1/2

Data readout

BBP- 812 Details
Canavan disease

Phase 1/2

Update

BBP-631 Details
Congenital adrenal hyperplasia

Phase 1/2

Update

Failed

Discontinued